Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.39 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | BAD | Q92934 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.38 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27834590 | 0.87 | KDM4E (0.44) | ALOX5KMT2ANPC1RAB9AALDH1A1 | |
| SCHEMBL980993 | 0.86 | ALDH1A1 (0.47) | ALOX5MEN1KMT2ANPC1RAB9A | |
| SCHEMBL2056898 | 0.85 | KDM4E (0.50) | NPC1RAB9AIKBKBALDH1A1HSD17B10 | |
| SCHEMBL980677 | 0.83 | PIN1 (0.50) | PTGDR2CSNK2A1 | |
| SCHEMBL3345496 | 0.82 | KMO (0.45) | ALDH1A1HSD17B10HCRTR1HCRTR2HPGD | |
| SCHEMBL270942 | 0.80 | HCRTR1 (0.51) | ALOX5HCRTR1HCRTR2PTGS2 | |
| SCHEMBL984634 | 0.80 | HCRTR1 (0.45) | MEN1KMT2ANPC1ALDH1A1HCRTR1 | |
| SCHEMBL3004677 | 0.78 | MAPK14 (0.44) | MAPK14ALOX5PTGDR2BCL2L1BAD | |
| SCHEMBL14705609 | 0.78 | MAPK14 (0.44) | MAPK14ALOX5KMT2ANPC1PTGDR2 | |
| SCHEMBL984890 | 0.77 | HCRTR1 (0.38) | NPC1RAB9AALDH1A1HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102164896-A | Phenethylamide derivatives and their heterocyclic analogues | ACTELION PHARMACEUTICALS LTD | 2011-08-24 | — | — | CN | claimed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | claimed |
| WO-2013050938-A1 | 3,7-DIAZABICYCLO[3.3.1]NONANE AND 9-OXA-3,7-DIAZABICYCLO[3.3.1]NONANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-04-11 | — | — | WO | disclosed |
| US-8236801-B2 | 2-aza-bicyclo[2.2.1]heptane derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-08-07 | — | — | US | disclosed |
| EP-2247586-B1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2012-04-25 | — | — | EP | disclosed |
| CN-102164896-A | Phenethylamide derivatives and their heterocyclic analogues | ACTELION PHARMACEUTICALS LTD | 2011-08-24 | — | — | CN | disclosed |
| CN-102083827-A | Thiazolidine compounds as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD | 2011-06-01 | — | — | CN | disclosed |
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-05-05 | — | — | US | disclosed |
| CN-101965343-A | 2-aza-bicyclo[2.2.1]heptane derivatives | ACTELION PHARMACEUTICALS LTD | 2011-02-02 | — | — | CN | disclosed |
| US-20110009401-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-2247586-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010044054-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-22 | — | — | WO | disclosed |
| WO-2010038200-A1 | OXAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-04-08 | — | — | WO | disclosed |
| WO-2010004507-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-01-14 | — | — | WO | disclosed |
| WO-2009104155-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105491-A1 | THIAZOLIDINE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, OXTR | MAPK14 3187/4885ALOX5 2436/4885MEN1 659/4885 |
| US-20110009401-A1 | 2-AZA-BICYCLO[2.2.1]HEPTANE DERIVATIVES | HCRTR2, HCRTR1, HCAR2 | MAPK14 2800/4885ALOX5 1017/4885MEN1 859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.